What Bebig does

Bebig is a Russian medical technology company headquartered in Moscow that specializes in the preparation and packaging of radioactive sources for brachytherapy and adjacent radiation oncology applications. The business is structured as a private Russian limited liability company (ООО «БЕБИГ») operating from a single Moscow office with a workforce of 11–50 employees. The company's remit spans the full brachytherapy continuum—from low-dose prostate cancer treatment to high-dose, image-guided, and intraoperative radiation therapy across multiple tumor types.

The product portfolio covers seven core platforms. For low-dose brachytherapy, Bebig produces I-125 microseeds used in minimally invasive prostate cancer treatment. For liver cancer, Bebig manufactures Y-90 microspheres used in radioembolization, claiming to be the first Russian domestic producer in this category and positioning the product as nuclear medicine import substitution. For high-dose brachytherapy, the Multisource and SagiNova systems deliver remote high-dose-rate radiation using Co-60 and Ir-192 isotopes, paired with the SagiPlan dosimetry planning software. The portfolio also includes a targeted fusion biopsy system (MRI–ultrasound image registration for prostate diagnostics), Ru-106 ophthalmological applicators for eye tumors, the Womed device for superficial and intraoperative radiation therapy, and the Biobeam blood, blood-component, tissue, and organ irradiation system.

The business model is a hybrid equipment, consumable, and services model sold via direct enterprise field sales to Russian oncology hospitals and cancer centers. Revenue is generated through capital equipment sales (Multisource, SagiNova, fusion biopsy, Biobeam, Womed), recurring consumables (I-125 microseeds, Y-90 microspheres, Ru-106 applicators), and service/maintenance plus physician training contracts. Critically, Bebig's low-dose brachytherapy treatment has been included in the Russian state High-Tech Medical Care (VMP) program, meaning treatments using the technology are government-funded for Russian citizens. Named partners and customers are concentrated in Russian state and academic oncology institutions (Blokhin NMIC, NMIC Radiology, Hospital No. 122, Sevastopol Oncology Center, Tyumen State Medical University), with one international reference site in Bratislava, Slovakia. The company is ISO 13485:2016 certified and reports no public listing, ticker, or institutional investor disclosures.

Name

Bebig

Legal name

ООО «БЕБИГ»

Website

https://bebig.ru

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Bebig is a Russian medical technology company that manufactures radioactive sources and brachytherapy systems—including I-125 prostate microseeds, Y-90 liver microspheres, high-dose Co-60/Ir-192 delivery systems, and related planning software—sold to state oncology hospitals and cancer centers, with treatments partially covered by Russian state High-Tech Medical Care programs.

Ownership category

akta.pro rank

Product category

Radiation Oncology and Brachytherapy Systems

NAICS

Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Brachytherapy medical devices
• Radiation oncology systems
• Prostate cancer treatment
• Liver cancer radioembolization
• Medical isotope products

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical devices and equipment: Sale and service of brachytherapy equipment including Multisource and SagiNova high-dose therapy systems, planning software (SagiPlan), and Womed intraoperative radiation therapy devices
2. Consumables and microseeds: I-125 microseeds for low-dose brachytherapy, Y-90 microspheres for liver cancer treatment, and Ru-106 ophthalmological applicators
3. Service and training: Service maintenance for therapy equipment, physician training programs in Russia and abroad, and organization of brachytherapy treatment rooms in clinics

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Bebig develops, manufactures, and supplies brachytherapy and radiation oncology products for cancer treatment. The portfolio includes I-125 low-dose microseeds for prostate cancer brachytherapy, Y-90 microspheres for liver cancer radioembolization, Multisource and SagiNova high-dose brachytherapy systems using Co-60 and Ir-192 isotopes, SagiPlan dosimetry software, MRI/ultrasound fusion biopsy systems, Ru-106 ophthalmic applicators, Womed intraoperative radiation therapy devices, and Biobeam blood irradiation systems, complemented by service maintenance, physician training, and brachytherapy room organization services.

Product overview

Bebig is a Russian medical technology company specializing in advanced brachytherapy and radiation oncology products. The company's portfolio includes low-dose rate brachytherapy micro-sources (I-125) for prostate cancer treatment, Y-90 microspheres for radioembolization of liver tumors, high-dose rate brachytherapy systems (Multisource, SagiNova, SagiPlan) using Co-60 and Ir-192 isotopes, fusion biopsy systems for prostate cancer diagnosis, Ru-106 ophthalmic applicators, Womed devices for intraoperative radiation therapy, and Biobeam blood irradiation systems. The company operates as a unified product portfolio focused on nuclear medicine and radiation oncology solutions for cancer treatment across multiple treatment areas including prostate cancer, liver cancer, and eye tumors.

Differentiator

Problem solved

Functional benefit

Brands

• SagiNova: High-dose brachytherapy system for remote introduction of high-dose radioactive preparations
• SagiPlan
• Multisource
• Biobeam
• Womed

Products and services

• I-125 Microseeds for Low-Dose Brachytherapy

Quantifiable outcome

• 10-year survival rate averages 87% according to various studies
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Sevastopol Oncology CenterminorStrategic or Co-development Partner · 5 May 2026Recently began performing radioembolization of liver tumors using Bebig-produced Y-90 microspheres as of May 2026.
• FSBI NMITs Oncology named after N.N. Blokhin of the Ministry of Health of RussiacoreStrategic or Co-development PartnerMajor national oncology center collaborating with Bebig on brachytherapy treatments. The center's deputy director for development of oncological care in regions serves as an expert advocate for brachytherapy as an innovative method combining advanced technologies with excellent results and minimally invasive techniques.
• FSBI NMIC Radiology of the Ministry of Health of RussiacoreStrategic or Co-development PartnerLeading national radiology center under the Ministry of Health, headed by the Chief внештатный oncologist of Russia. The center collaborates with Bebig as an example of quality and reliable import substitution, particularly in radiofarm production with Russian Y-90 microspheres.
• FMBU Clinical Hospital No. 122 named after L.G. SokolovcoreStrategic or Co-development PartnerLeading brachytherapy center performing prostate cancer treatments. The hospital's Prostate Cancer Brachytherapy Center, led by a Prize laureate of the St. Petersburg Government, uses Bebig technology exclusively.
• Tyumen State Medical University Oncology DepartmentminorStrategic or Co-development PartnerAcademic institution conducting research on brachytherapy effectiveness, with studies reporting 87% 10-year survival rates.
• Saint Elizabeth Oncology Institute (Bratislava, Slovakia)minorStrategic or Co-development PartnerInternational reference center using Bebig technology, with published studies confirming brachytherapy effectiveness for prostate cancer across risk groups.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Boston Scientific (TheraSphere): Boston Scientific's TheraSphere Y-90 glass microspheres compete head-to-head with Bebig's Y-90 product for liver cancer radioembolization procedures across major cancer centers.
• Varian (Siemens Healthineers): Varian offers the GammaMed, VariSource, and Bravos HDR brachytherapy afterloaders and the BrachyVision planning system, directly competing with Bebig's high-dose brachytherapy portfolio in hospitals globally.
• IsoRay Medical: IsoRay manufactures Cesium-131 and I-125 brachytherapy seeds for prostate and other cancers - directly comparable isotope-based seed product category to Bebig's I-125 microseeds.
• Nordion (Sotera Health): Nordion supplies medical isotopes including Co-60 and I-125 used in brachytherapy devices and sterilization - a key input supplier and indirect competitor to Bebig's vertically integrated isotope production.
• Theragenics: Theragenics produces brachytherapy seeds (I-125, Pd-103) and operates the Galt Medical and surgical products businesses, overlapping directly with Bebig's brachytherapy seed and applicator portfolio.
• Eckert & Ziegler (BEBIG GmbH): Eckert & Ziegler acquired the original German BEBIG and produces HDR brachytherapy afterloaders (Multisource, SagiNova) and I-125 seeds that Bebig (Russia) distributes alongside its own microsphere production. Directly comparable product portfolio and isotope-based technology.
• Sirtex Medical: Sirtex manufactures SIR-Spheres Y-90 resin microspheres for liver radioembolization - the global benchmark for the product that Bebig is producing domestically in Russia. Closest direct competitor in the Y-90 microsphere category.
• Elekta: Elekta is the global leader in HDR brachytherapy afterloaders (Flexitron), treatment planning software, and applicators - directly competing with Bebig's Multisource/SagiNova systems and SagiPlan planning software in radiation oncology.

Regional players

• BEBIG Medical (China): The Chinese BEBIG Medical entity sells Eckert & Ziegler-derived brachytherapy products (HDR afterloaders, seeds) into the Chinese and Asian markets - same product lineage as the systems Bebig (Russia) distributes, but serving a different geography without direct overlap.

Emerging players

• Mevion Medical Systems: Mevion develops compact proton therapy systems as an alternative radiation oncology modality; not a direct brachytherapy peer but competes for radiation oncology capital budgets at the same hospitals Bebig sells into.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brand-strategy-and-innovation-marketing

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bebig